Novodol (levonorgestrel + ethinyloestradiol): Uses, Dosage & Side Effects

What it's for (Indications)

Levonorgestrel + ethinyloestradiol, a combination oral contraceptive, is primarily indicated for the prevention of pregnancy.
This medication works by employing two synthetic hormones to disrupt the natural ovulatory cycle, thereby making conception highly improbable.
Beyond its principal role in contraception, this pharmaceutical formulation is frequently utilized to regulate menstrual cycles, addressing issues such as irregular bleeding patterns, excessive menstrual flow (menorrhagia), and painful menstruation (dysmenorrhea).
While its primary approval is for contraception, the systemic hormonal effects often confer these additional therapeutic benefits, significantly improving quality of life for many users.
It is crucial to understand that while highly effective for birth control, it does not offer protection against sexually transmitted infections (STIs).
Patients should be counseled regarding the importance of safe sexual practices to prevent STI transmission.

Dosage Information

Type	Guideline
Standard	The typical dosage regimen for levonorgestrel + ethinyloestradiol involves taking one tablet orally at the same time each day, usually starting on the first day of menstruation or the first Sunday following the start of menstruation. Most standard packs consist of 21 active hormone-containing tablets followed by 7 inactive (placebo) tablets, completing a 28-day cycle. During the 7 placebo days, a withdrawal bleed similar to a menstrual period usually occurs. Adherence to the daily regimen is paramount for optimal contraceptive efficacy. If a dose is missed, specific instructions apply depending on how many doses were missed and when in the cycle the omission occurred. Generally, a single missed active tablet should be taken as soon as remembered, and the next tablet taken at the usual time, even if it means taking two tablets in one day. Consulting the patient information leaflet or a healthcare provider is essential for detailed guidance on missed doses and to ensure continued contraceptive protection.

Type

Guideline

Standard

The typical dosage regimen for levonorgestrel + ethinyloestradiol involves taking one tablet orally at the same time each day, usually starting on the first day of menstruation or the first Sunday following the start of menstruation. Most standard packs consist of 21 active hormone-containing tablets followed by 7 inactive (placebo) tablets, completing a 28-day cycle. During the 7 placebo days, a withdrawal bleed similar to a menstrual period usually occurs. Adherence to the daily regimen is paramount for optimal contraceptive efficacy. If a dose is missed, specific instructions apply depending on how many doses were missed and when in the cycle the omission occurred. Generally, a single missed active tablet should be taken as soon as remembered, and the next tablet taken at the usual time, even if it means taking two tablets in one day. Consulting the patient information leaflet or a healthcare provider is essential for detailed guidance on missed doses and to ensure continued contraceptive protection.

Safety & Warnings

Common Side Effects

Commonly reported side effects associated with levonorgestrel + ethinyloestradiol include nausea, headache, breast tenderness or pain, breakthrough bleeding (spotting or bleeding between periods), changes in menstrual flow, mood alterations (including depression or anxiety), weight fluctuations, and abdominal cramping.
These side effects are often mild and may diminish after the first few cycles as the body adjusts to the hormones.
Less common but potentially serious side effects include an increased risk of blood clots (venous thromboembolism, e.
g.
, deep vein thrombosis or pulmonary embolism), arterial thrombotic events (e.
g.
, myocardial infarction or stroke), hypertension, gallbladder disease, and rare liver tumors.
Any persistent, severe, or unusual symptoms such as sudden severe headache, chest pain, vision changes, or leg pain/swelling should be promptly reported to a healthcare provider for evaluation as they may indicate serious adverse events requiring immediate medical attention.

Serious Warnings

Black Box Warning: **WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS** Cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including levonorgestrel + ethinyloestradiol, are contraindicated in women who are over 35 years of age and smoke. This serious warning highlights the profound danger of the synergy between smoking and hormonal contraception on the cardiovascular system, encompassing risks such as myocardial infarction, stroke, and thromboembolism. Patients must be strongly advised against smoking while using this medication, and cessation counseling should be provided to reduce these life-threatening risks. Healthcare providers should thoroughly assess a woman's smoking status and age before prescribing this medication and re-evaluate periodically.
Patients using levonorgestrel + ethinyloestradiol should be aware of several important warnings beyond the Black Box Warning.
This medication does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs).
Women with a history of hypertension should be monitored closely, as oral contraceptives can elevate blood pressure.
Those with a history of migraine headaches, particularly with aura, are at an increased risk of stroke and should discuss alternatives with their physician.
Diabetes patients may experience changes in glucose tolerance, necessitating careful monitoring.
Liver function should be assessed in patients with a history of hepatic impairment.
Discontinue use if jaundice or significant liver dysfunction develops.
A change in mood or depressive symptoms should also be reported.
Use with caution in women with a family history of breast cancer or benign breast disease.
Certain medications, including rifampicin, some anticonvulsants (e.
g.
, carbamazepine, phenytoin), and St.
John's wort, can reduce the effectiveness of oral contraceptives and necessitate alternative contraception or dosage adjustments.

How it Works (Mechanism of Action)

Levonorgestrel + ethinyloestradiol exerts its primary contraceptive effect through a multifaceted mechanism involving both hormonal components. Ethinyloestradiol, a synthetic estrogen, primarily acts to suppress the release of Follicle-Stimulating Hormone (FSH) from the anterior pituitary gland, thereby inhibiting follicular development and growth within the ovaries. It also contributes to stabilizing the endometrium, reducing the incidence of breakthrough bleeding. Levonorgestrel, a synthetic progestin, acts synergistically by suppressing the Luteinizing Hormone (LH) surge, which is crucial for ovulation, thus preventing the release of an egg from the ovary (anovulation). Additionally, levonorgestrel induces changes in the cervical mucus, making it thicker and less penetrable for sperm, and alters the endometrial lining, rendering it less receptive to implantation should fertilization occur. These combined actions provide highly effective contraception by preventing conception at multiple physiological points.